Metalyse Contraindications

METALYSE is contraindicated in: Patients with known hypersensitivity to the active substance tenecteplase, gentamicin (a trace residue from the manufacturing process) or to any of the excipients.
Situations associated with a risk of bleeding such as: Significant bleeding disorder at present or within the past 6 months, known haemorrhagic diathesis; any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery); severe uncontrolled arterial hypertension (see Precautions); severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis; active ulcerative gastrointestinal disease; known arterial aneurysm and/or arterial/venous malformation; neoplasm with increased bleeding risk; bacterial endocarditis, perocarditis; acute pancreatitis.
Situations associated with a risk of bleeding such as: Haemorrhagic stroke or stroke of unknown origin at any time; ischaemic stroke or transient ischaemic attack (TIA) in the preceding 6 months; patients receiving effective oral anticoagulant treatment (e.g. vitamin K antagonists with INR >1.3) (see Bleeding under Precautions); major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months (this include any trauma associated with the current AMI), recent trauma to the head or cranium.